Cargando…

Development of a VLP-Based Vaccine Displaying an xCT Extracellular Domain for the Treatment of Metastatic Breast Cancer

Metastatic breast cancer (MBC) is the leading cause of cancer death in women due to recurrence and resistance to conventional therapies. Thus, MBC represents an important unmet clinical need for new treatments. In this paper we generated a virus-like particle (VLP)-based vaccine (AX09) to inhibit de...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rolih, Valeria, Caldeira, Jerri, Bolli, Elisabetta, Salameh, Ahmad, Conti, Laura, Barutello, Giuseppina, Riccardo, Federica, Magri, Jolanda, Lamolinara, Alessia, Parra, Karla, Valenzuela, Paloma, Francia, Giulio, Iezzi, Manuela, Pericle, Federica, Cavallo, Federica
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7352461/ https://www.ncbi.nlm.nih.gov/pubmed/32521631 http://dx.doi.org/10.3390/cancers12061492

Ejemplares similares

A Virus-Like-Particle immunotherapy targeting Epitope-Specific anti-xCT expressed on cancer stem cell inhibits the progression of metastatic cancer in vivo
por: Bolli, Elisabetta, et al.
Publicado: (2017)

Tumor-Associated Antigen xCT and Mutant-p53 as Molecular Targets for New Combinatorial Antitumor Strategies
por: Magri, Jolanda, et al.
Publicado: (2021)

Immunotherapy against the Cystine/Glutamate Antiporter xCT Improves the Efficacy of APR-246 in Preclinical Breast Cancer Models
por: Barutello, Giuseppina, et al.
Publicado: (2022)

Virus-Like Particles as an Immunogenic Platform for Cancer Vaccines
por: Caldeira, Jerri C., et al.
Publicado: (2020)

Cystine/glutamate antiporter xCT deficiency reduces metastasis without impairing immune system function in breast cancer mouse models
por: Ruiu, Roberto, et al.
Publicado: (2023)

Strengths and Weaknesses of Pre-Clinical Models for Human Melanoma Treatment: Dawn of Dogs’ Revolution for Immunotherapy
por: Barutello, Giuseppina, et al.
Publicado: (2018)

Role of ADCC, CDC, and CDCC in Vaccine-Mediated Protection against Her2 Mammary Carcinogenesis
por: Macagno, Marco, et al.
Publicado: (2022)

CSPG4: a prototype oncoantigen for translational immunotherapy studies
por: Rolih, Valeria, et al.
Publicado: (2017)

Role and Involvement of TENM4 and miR-708 in Breast Cancer Development and Therapy
por: Peppino, Giulia, et al.
Publicado: (2022)

Antitumor immunization of mothers delays tumor development in cancer-prone offspring
por: Barutello, Giuseppina, et al.
Publicado: (2015)

Maternal Immunization: New Perspectives on Its Application Against Non-Infectious Related Diseases in Newborns
por: Riccardo, Federica, et al.
Publicado: (2017)

Microenvironment, Oncoantigens, and Antitumor Vaccination: Lessons Learned from BALB-neuT Mice
por: Conti, Laura, et al.
Publicado: (2014)

HER2-Displaying M13 Bacteriophages induce Therapeutic Immunity against Breast Cancer
por: Wang, Junbiao, et al.
Publicado: (2022)

Antigen mimicry as an effective strategy to induce CSPG4-targeted immunity in dogs with oral melanoma: a veterinary trial
por: Riccardo, Federica, et al.
Publicado: (2022)

A vaccine targeting angiomotin induces an antibody response which alters tumor vessel permeability and hampers the growth of established tumors
por: Arigoni, Maddalena, et al.
Publicado: (2012)

Bovine herpesvirus 4-based vector delivering a hybrid rat/human HER-2 oncoantigen efficiently protects mice from autochthonous Her-2(+) mammary cancer
por: Jacca, Sarah, et al.
Publicado: (2015)

Identification of TENM4 as a Novel Cancer Stem Cell-Associated Molecule and Potential Target in Triple Negative Breast Cancer
por: Ruiu, Roberto, et al.
Publicado: (2021)

Inhibition of JAK3 with a novel, selective, and orally active small molecule induces therapeutic response in T-cell malignancies
por: Ross, Jeremy A., et al.
Publicado: (2013)

Angiomotin like-1 is a novel component of the N-cadherin complex affecting endothelial/pericyte interaction in normal and tumor angiogenesis
por: Zheng, Yujuan, et al.
Publicado: (2016)

VLP‐factory™ and ADDomer(©): Self‐assembling Virus‐Like Particle (VLP) Technologies for Multiple Protein and Peptide Epitope Display
por: Sari‐Ak, Duygu, et al.
Publicado: (2021)

Toll-Like Receptor 2 at the Crossroad between Cancer Cells, the Immune System, and the Microbiota
por: Di Lorenzo, Antonino, et al.
Publicado: (2020)

Immunization against ROS1 by DNA Electroporation Impairs K-Ras-Driven Lung Adenocarcinomas
por: Riccardo, Federica, et al.
Publicado: (2020)

Early onset and enhanced growth of autochthonous mammary carcinomas in C3-deficient Her2/neu transgenic mice
por: Bandini, Silvio, et al.
Publicado: (2013)

Thermal Stability of RNA Phage Virus-Like Particles Displaying Foreign Peptides
por: Caldeira, Jerri C, et al.
Publicado: (2011)

A hypoxic signature marks tumors formed by disseminated tumor cells in the BALB-neuT mammary cancer model
por: Msaki, Aichi, et al.
Publicado: (2016)

Teneurins: Role in Cancer and Potential Role as Diagnostic Biomarkers and Targets for Therapy
por: Peppino, Giulia, et al.
Publicado: (2021)

Interaction between Borrelia miyamotoi variable major proteins Vlp15/16 and Vlp18 with plasminogen and complement
por: Schmidt, Frederik L., et al.
Publicado: (2021)

Display of single-chain variable fragments on bacteriophage MS2 virus-like particles
por: Lino, Christopher A., et al.
Publicado: (2017)

Design of a VLP-nanovehicle for CYP450 enzymatic activity delivery
por: Sánchez-Sánchez, Lorena, et al.
Publicado: (2015)

Protection of mice against the highly pathogenic VV(IHD-J) by DNA and fowlpox recombinant vaccines, administered by electroporation and intranasal routes, correlates with serum neutralizing activity
por: Bissa, Massimiliano, et al.
Publicado: (2016)

On the Effect of Thermodynamic Equilibrium on the Assembly Efficiency of Complex Multi-Layered Virus-Like Particles (VLP): the Case of Rotavirus VLP
por: Roldão, António, et al.
Publicado: (2012)

RNA Phage VLP-Based Vaccine Platforms
por: Peabody, David S., et al.
Publicado: (2021)

Erythro-VLP: Erythrocyte Virus-Like-Particles
por: Himbert, Sebastian, et al.
Publicado: (2021)

Resolvin D1 reduces cancer growth stimulating a protective neutrophil-dependent recruitment of anti-tumor monocytes
por: Mattoscio, Domenico, et al.
Publicado: (2021)

Virus-like particle (VLP)-based vaccines for pandemic influenza: Performance of a VLP vaccine during the 2009 influenza pandemic
por: López-Macías, Constantino
Publicado: (2012)

A cVLP-Based Vaccine Displaying Full-Length PCSK9 Elicits a Higher Reduction in Plasma PCSK9 Than Similar Peptide-Based cVLP Vaccines
por: Goksøyr, Louise, et al.
Publicado: (2022)

Gemcitabine and XCT790, an ERRα inverse agonist, display a synergistic anticancer effect in pancreatic cancer
por: Liu, Shi-lei, et al.
Publicado: (2022)

The transmembrane replacement H7N9-VLP vaccine displays high levels of protection in mice
por: Qin, Jianru, et al.
Publicado: (2022)

Zika virus-like particle (VLP) based vaccine
por: Boigard, Hélène, et al.
Publicado: (2017)

Large-scale production and purification of VLP-based vaccines
por: Vicente, Tiago, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_bcom1545vqfbovmqniqfkf6h8m